Some Bias Claims Of Ex-Biopharma Execs Sent To Arbitration
Two biopharmaceutical executives must resolve some of their sex bias and retaliation claims against their ex-employer outside of court, despite a new federal law blocking the arbitration of sexual misconduct claims,...To view the full article, register now.
Already a subscriber? Click here to view full article